Hepatitis C and fibrosis

Aguilera, Victoria; Berenguer, Marina

doi:10.4321/s1130-01082004000600006

Cited by 4 publications

(6 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hepatitis C virus (HCV) infection causes liver damage in many patients with the development of varying degrees of inflammation and fibrosis. The main complication of chronic HCV infection is liver fibrosis 2 . The fibrotic tissue can be increased by intrahepatic hypoxia.…”

Section: Introductionmentioning

confidence: 99%

Vascular Endothelial Growth Factor Levels in Chronic Hepatitis and Liver Cirrhosis Associated with Hepatitis C

Çadırcı¹,

Keskin²

2019

Kafkas J Med Sci

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Vascular Endothelial Growth Factor Levels in Chronic Hepatitis and Liver Cirrhosis Associated with Hepatitis C

Çadırcı¹,

Keskin²

2019

Kafkas J Med Sci

View full text Add to dashboard Cite

show abstract

“…Hepatitis C virus was discovered 27 years ago and this chronic infection is the main cause of end‐stage liver disease, hepatocellular carcinoma, and other liver‐related deaths . Approximately 180 million people from around the world are chronically infected with the HCV and the individual impact ranges from minimal histological changes to fibrosis and cirrhosis . Hepatitis C‐induced fibrosis in patients who attained sustained viral response (SVR) has a low, but real risk of hepatocellular carcinoma .…”

Section: Introductionmentioning

confidence: 99%

Real‐world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis

Preda

Popescu

Băicuș

et al. 2017

Liver International

View full text Add to dashboard Cite

show abstract

“…Chronic hepatitis C (CHC) is a progressive disease characterized by the development of hepatocellular necrosis, inflammation, and fibrosis (1,2). It has been shown that angiogenesis, the formation of new blood vessels, occurs in various liver diseases; hepatocellular carcinoma is the condition where this phenomenon has been best described, but it has also been recognized in CHC (3,4).…”

Section: Introductionmentioning

confidence: 99%

Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients

Mora

Sanz-Cameno

Medina

et al. 2005

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Objectives: our objectives were to compare angiogenesis soluble factor (ASF) levels in chronic hepatitis C (CHC) patients and healthy individuals, and to investigate potential associations between ASF levels and both histological and biochemical markers of disease progression.Method: thirty-six patients (69% males) positive for HCV-RNA by PCR analysis were included in the study. All patients underwent liver biopsy before treatment. Serum levels of vascular endothelial growth factor (VEGF), soluble Flt-1 and Flk-1 receptors, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and soluble Tie-2 receptor were determined by ELISA. Fifteen healthy subjects were used as controls.Results: in comparison to healthy individuals, CHC patients showed significantly increased serum levels of proangiogenic factors PlGF (22 ± 5 vs. 18 ± 8 pg/ml; p < 0.05), Ang-2 (1265 ± 385 vs. 833 ± 346 pg/ml; p < 0.005) and sFlt-1 (95 ± 22 vs. 72 ± 14 pg/ml; p < 0.0001). Interestingly, in CHC patients serum levels of VEGF and Tie-2 correlated with grade of inflammation, PlGF correlated with stage of fibrosis, and Flt-1 and Flk-1 correlated with serum transaminase levels (p < 0.05 in all cases).Conclusions: CHC patients showed increased serum levels of ASF, and a significant correlation was shown between serum levels of selected ASFs and grade of inflammation, stage of fibrosis, and transaminase levels.

show abstract

Hepatitis C and fibrosis

Cited by 4 publications

References 70 publications

Vascular Endothelial Growth Factor Levels in Chronic Hepatitis and Liver Cirrhosis Associated with Hepatitis C

Vascular Endothelial Growth Factor Levels in Chronic Hepatitis and Liver Cirrhosis Associated with Hepatitis C

Real‐world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis

Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients

Contact Info

Product

Resources

About